Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

182 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world data on NGS using the Oncomine DxTT for detecting genetic alterations in non-small-cell lung cancer: WJOG13019L.
Sakata S, Otsubo K, Yoshida H, Ito K, Nakamura A, Teraoka S, Matsumoto N, Shiraishi Y, Haratani K, Tamiya M, Ikeda S, Miura S, Tanizaki J, Omori S, Yoshioka H, Hata A, Yamamoto N, Nakagawa K. Sakata S, et al. Among authors: tamiya m. Cancer Sci. 2022 Jan;113(1):221-228. doi: 10.1111/cas.15176. Epub 2021 Nov 7. Cancer Sci. 2022. PMID: 34704312 Free PMC article.
Phase I study of intravenous ASA404 (vadimezan) administered in combination with paclitaxel and carboplatin in Japanese patients with non-small cell lung cancer.
Hida T, Tamiya M, Nishio M, Yamamoto N, Hirashima T, Horai T, Tanii H, Shi MM, Kobayashi K, Horio Y. Hida T, et al. Among authors: tamiya m. Cancer Sci. 2011 Apr;102(4):845-51. doi: 10.1111/j.1349-7006.2010.01839.x. Epub 2011 Feb 8. Cancer Sci. 2011. PMID: 21205086 Free article. Clinical Trial.
Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Tamiya A, Tamiya M, Shiroyama T, Saijo N, Nakatani T, Minomo S, Tsuji T, Takeuchi N, Omachi N, Kurata K, Suzuki H, Okamoto N, Okishio K, Hirashima T, Atagi S. Tamiya A, et al. Among authors: tamiya m. Med Oncol. 2015 Mar;32(3):40. doi: 10.1007/s12032-014-0474-x. Epub 2015 Jan 25. Med Oncol. 2015. PMID: 25616723 Clinical Trial.
A phase II study of pemetrexed plus carboplatin followed by maintenance pemetrexed as first-line chemotherapy for elderly patients with advanced non-squamous non-small cell lung cancer.
Tamiya M, Tamiya A, Kaneda H, Nakagawa K, Yoh K, Goto K, Okamoto H, Shimokawa T, Abe T, Tanaka H, Daga H, Takeda K, Hirashima T, Atagi S. Tamiya M, et al. Among authors: tamiya a. Med Oncol. 2016 Jan;33(1):2. doi: 10.1007/s12032-015-0715-7. Epub 2015 Nov 24. Med Oncol. 2016. PMID: 26603297 Clinical Trial.
Phase II study of S-1 plus bevacizumab combination therapy for patients previously treated for non-squamous non-small cell lung cancer.
Nishijima-Futami Y, Minami S, Futami S, Koba T, Higashiguchi M, Tamiya M, Suzuki H, Hirashima T, Komuta K, Kijima T. Nishijima-Futami Y, et al. Among authors: tamiya m. Cancer Chemother Pharmacol. 2017 Jun;79(6):1215-1220. doi: 10.1007/s00280-017-3321-x. Epub 2017 Apr 28. Cancer Chemother Pharmacol. 2017. PMID: 28455584 Clinical Trial.
Analysis of Early Death in Japanese Patients With Advanced Non-small-cell Lung Cancer Treated With Nivolumab.
Inoue T, Tamiya M, Tamiya A, Nakahama K, Taniguchi Y, Shiroyama T, Isa SI, Nishino K, Kumagai T, Kunimasa K, Kimura M, Suzuki H, Hirashima T, Atagi S, Imamura F. Inoue T, et al. Among authors: tamiya a, tamiya m. Clin Lung Cancer. 2018 Mar;19(2):e171-e176. doi: 10.1016/j.cllc.2017.09.002. Epub 2017 Oct 13. Clin Lung Cancer. 2018. PMID: 29133121
182 results